# US 2016/0257682 A1 · Azaindazole compounds as inhibitors of t790m containing egfr mutants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0257682 A1
- Document ID: US20160257682A1
- Status: Published application
- Kind: A1
- Application number: 15/152,947
- Filed: 2016-05-12
- Published: 2016-09-08
- Earliest claimed: 2013-06-28
- Assignees: Genentech, Inc.
- Applicants: Genentech, Inc.
- Inventors: Marian C. Bryan; Bryan Chan; Francois Diederich; Jennafer Dotson; Emily Hanan; Timothy Heffron; Michael Lainchbury
- Web page: https://patentgrep.com/patent/US20160257682A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/5386: spiro-condensed or forming part of bridged ring systems
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to novel compounds which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer.

## Claims

### Claim 1

A compound of Formula (I)
wherein,
R1 is C3-C7heterocycloalkyl, heteroaryl, —O(C1-C6alkyl), or —NRaRb, wherein said C3-C7heterocycloalkyl and heteroaryl may be further substituted with one to five Rf groups;
R2 is hydrogen, C1-C6alkyl, C3-C7cycloalkyl or C3-C7heterocycloalkyl;
R3 is C1-C6alkyl, C3-C7heterocycloalkyl, C3-C7cycloalkyl, —O(C1-C6alkyl), CN, —NRaRb, —NHC(O)(C1-C3alkyl), —C(O)NRaRb or heteroaryl;
wherein each Rf is independently selected from the group consisting of C1-C3alkyl, alkoxy, amino, hydroxy, alkylamino, amide, urea, oxo, halo, pyrazolyl, imidazolyl, triazolyl, CN, —NHC(O)(C1-C3alkyl), acyl, sulfonyl, sulfoxide, sulfonamide, sulfoximinyl, —(CH2)mC3-C7heterocycloalkyl, —O(C1-C6alkyl), —C(O)ORa;
wherein each Ra is independently H or C1-C6alkyl, each Rb is independently H, C1-C6alkyl, alkoxy, amino, —(CH2)mC(O)NH2, —(CH2)mC3-C7cycloalkyl, —(CH2)mC3-C7heterocycloalkyl or —(CH2)mheteroaryl, or Ra and Rb together may form a C3-C7cycloalkyl, C3-C7heterocycloalkyl or heteroaryl ring, wherein said C3-C7cycloalkyl, C3-C7heterocycloalkyl and heteroaryl may each be further substituted with one to three groups selected from the group consisting of halo, hydroxy, C1-C3alkyl, amino, oxo, amide, sulfonyl, sulfoxide, sulfoximinyl, sulfonamide, alkoxy, CN and acyl;
each m is independently 0, 1, 2 or 3;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein R1 is C3-C7heterocycloalkyl; or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

A compound according to claim 1, wherein R1 is heteroaryl; or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

A compound according to claim 1, wherein R1 is —NRaRb; or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

A compound of claim 1, wherein R1 is heteroaryl or C3-C7heterocycloalkyl, Rf is sulfonyl or alkoxy, R3 is —NRaRb or heteroaryl, R2 is C1-C6alkyl, or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 5)

A compound of claim 5, wherein R1 is piperdinyl or pyrazolyl, or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

A compound of claim 1, wherein Rf is —SO2(cyclopropyl), halo, hydroxy, C1-C6alkyl or methoxy, or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

A compound according to claim 1, wherein R2 is C1-C6alkyl;

### Claim 9 (depends on 8)

A compound according to claim 8, wherein R3 is C1-C3alkyl, C3-C7heterocycloalkyl, heteroaryl, —NRaRb or —C(O)NRaRb; or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1)

A compound according to claim 1, wherein R1 is a C3-C7heterocycloalkyl or heteroaryl selected from the group consisting of piperidinyl and pyrazolyl, wherein said C3-C7heterocycloalkyl or heteroaryl may be further substituted with one to three Rf groups selected from C1-C6alkyl, alkoxy, hydroxyl, halo, sulfonyl, and sulfonamide; or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1)

A compound according claim 1, wherein R2 is isopropyl, sec-butyl or 1,1,1-trifluoropropan-2-yl; or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 13 (depends on 1)

A method of treating cancer comprising administering to a human in need thereof an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof in a pharmaceutical composition.

### Claim 14 (depends on 1)

A use of a compound according to claim 1 in the preparation of a medicament for the treatment of cancer.

### Claim 15 (depends on 13)

A method of claim 13, wherein said cancer is non-small cell lung cancer.

### Claim 16 (depends on 14)

A use of claim 14, wherein said cancer is non-small cell lung cancer.

### Claim 17 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof for use in therapy.

### Claim 18 (depends on 1)

A method of treating cancer comprising co-administering to a human in need thereof a combination of an effective amount of an anti-neoplastic agent in a pharmaceutical composition and a compound according to claim 1 or a pharmaceutically acceptable salt thereof in a pharmaceutical composition.

### Claim 19 (depends on 18)

A method of claim 18, wherein said cancer is non-small cell lung cancer.

### Claim 20 (depends on 19)

A method of claim 19, wherein said anti-neoplastic agent is erlotinib or gefitinib.

### Claim 21 (depends on 1)

A use of a combination of an anti-neoplastic agent and a compound according to claim 1 or a pharmaceutically acceptable salt thereof in preparation of a medicament for the treatment of cancer.

### Claim 22 (depends on 21)

A use of claim 21, wherein said cancer is non-small cell lung cancer.

### Claim 23 (depends on 21)

A use of claim 21, wherein said anti-neoplastic agent is erlotinib or gefitinib.
